Improving Treatment for IPF Request More Information Trial Objective Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Adults 40 years of age and older. Age: 40+ Gender: Any Gender Estimated Time Commitment 8 visits to the study center, plus phone visits to review lab results Visits will take two to four hours. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Not Provided Travel Reimbursement: Not Available Trial Contact For more information, contact: Kaitlin Fier 303.270.2852 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors National Institutes of Health Principal Investigators Gregory Downey, MD + × Gregory Downey, MD Professor Executive Vice President, Academic Affairs Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 5 out of 5 stars Make an Appoinment Co-Investigators Kevin Brown, MD + × Kevin Brown, MD Chair, Department of Medicine Professor of Medicine Department of Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available.